$ATAI

Barrett Christopher Ryan Cave sold (to issuer) 155,066 shares of ATAI

Barrett Christopher Ryan Cave (See remarks) sold (to issuer) 155,066 shares of AtaiBeckley Inc. (ATAI) on 2026-09-11.

Original reporting
SEC EDGAR · Barrett Christopher Ryan Cave
Published Sep 11, 2026, 9:44 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 11, 2026, 9:55 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ATAI
Neutral
medium confidence
Mentioned
$ATAI
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ATAINeutralLow
01

Why it matters

Insider sales to the issuer can be routine and may not carry strong information content, especially when price and total value are not provided.

02

Market read

Traders may note the insider reducing direct holdings to zero, but the lack of disclosed price/value limits tradable inference.

03

What to watch

Because the price and total value are not disclosed here, traders cannot infer economic magnitude; also, the holdings after transaction show 0 shares, which may reflect plan mechanics rather than conviction.

Relevance 4/10Novelty 4/10Timing: filed 2026-09-11 (after-hours SEC Form 4 disclosure)

Background

The article is an SEC Form 4 insider transaction disclosure for AtaiBeckley Inc. (ATAI).

Company-level read

Ticker impact

$ATAINeutralMedium confidence
Context

AtaiBeckley Inc. (ATAI) disclosed an officer sale to the issuer of 155,066 shares on 2026-09-11 via an SEC Form 4.

Expected impact

Low likelihood of a sustained price move; any reaction is likely muted and short-lived.

Evidence & confidence

The filing is primary-source (Form 4) but lacks price and total value, and the transaction code indicates sale to issuer (often buyback-related), which typically has limited directional signal versus open-market sales.

Market effects

Minimal. Insider Form 4 activity without disclosed valuation generally does not reset biotech sector expectations.

None indicated.

None indicated.

Counterpoint

The transaction could be part of a structured buyback or liquidity mechanism, so it may not reflect bearish insider views at all.

Key entities

  • AtaiBeckley Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Barrett Christopher Ryan Cave

    Officer who sold 155,066 shares to the issuer on 2026-09-11.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LLYMedAI 8/10

$35 Billion Frog Drug Deal Explained: The Psychedelic Treatment That Could Change Depression Therapy

Eli Lilly is reportedly investing $35 billion in ATAI Life Sciences' psychedelic drug BPL-003, derived from a compound found in the Sonoran Desert toad, for treating depression. Clinical trials showed improvements in treatment-resistant depression patients, but long-term effects are still under study. The drug aims to promote neuroplasticity, potentially helping patients break negative thought patterns. Researchers caution that results do not prove a permanent cure.

$LLYHighAI 9/10

Eli Lilly (LLY) Finalizes $2.8B AtaiBeckley Acquisition for Depression Treatment Pipeline

Eli Lilly (LLY) completed its $2.8B acquisition of AtaiBeckley (ATAI) on September 11, 2026. AtaiBeckley shareholders received $6.75 per share plus contingent value rights (CVRs) worth up to $2.50 per share. AtaiBeckley shares rose 80% in the six months before the deal, closing at $7.35. The company will delist from Nasdaq. LLY shares closed at $1,119.26, down 0.33%.

$LLYMedAI 9/10

Lilly Completes AtaiBeckley Acquisition to Expand Mental Health Pipeline

Eli Lilly (LLY) completed its acquisition of AtaiBeckley, adding a clinical-stage portfolio of rapid-acting neuroplastogens to its neuroscience pipeline. The deal expands Lilly's focus on treatment-resistant depression and other mental health conditions, with BPL-003 as the lead program. Financial terms were not disclosed.

$LLYMedAI 8/10

Share AtaiBeckley Buyout – Minichart

Eli Lilly completed its $6.75-per-share acquisition of AtaiBeckley Inc., taking the company private. Shareholders received $6.75 in cash plus contingent value rights (CVRs) worth up to $2.50 more if milestones are met. AtaiBeckley's stock will be delisted from Nasdaq.